Company news

Paradigm Biopharmaceuticals Ltd. news in 2018

Paradigm Biopharmaceuticals Ltd.'s news releases, calls and decks from 2018, newest first.

View company

Paradigms supplementary Phase 2B data

December 19, 2018

Presentation of Phase 2 clinical trial results

December 17, 2018

PAR reports successful Phase 2 clinical trial

December 17, 2018

Paradigm reports consistent OA pain reduction

December 6, 2018

Paradigms AGM Presentation

November 26, 2018

Paradigm in-licenses treatment for rare joint disease

November 21, 2018

Paradigm receives $2.32m R&D tax incentive refund

November 14, 2018

PAR reports pain reduction in 145 people with osteoarthritis

November 7, 2018

Paradigm Agreement With USA Past Players Network

October 24, 2018

Paradigms Updated Corporate Presentation

October 24, 2018

Paradigm Raises A$9 Million

October 24, 2018

PAR reports pain reduction in OA patients

September 24, 2018

Phase2a RossRiver Virus Clinical Trial Recruitment Finalised

August 28, 2018

Appendix 4E and 2018 Annual Report

August 24, 2018

PAR achieves 60 per cent reduction in osteoarthritis pain

August 14, 2018

PAR achieves 100 per cent recruitment in Phase 2b OA Trial

August 5, 2018

PAR - 50% reduction in osteoarthritis pain maintained

June 14, 2018

Paradigm OA Phase 2b Clinical Trial over 80% Recruited

May 16, 2018

Paradigms phase 2 clinical data update

March 26, 2018

Paradigm reports osteoarthritis pain reduced by 50%

February 28, 2018

Half Year Accounts

February 22, 2018

Quarterly Update and Appendix 4C

January 29, 2018

PARs European Patent Granted for Bone Marrow Edema Lesions

January 15, 2018

Decks in 2018